Lipooligosaccharide based vaccine for prevention of moraxella (branhamella)catarrhalis infections in humans
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsXin-Xing Gu, John B. Robbins
Life of this patent
Estimating the term…
Abstract
A conjugate vaccine for Moraxella (Branhamella) catarrhalis comprising isolated lipooligosaccharide from which esterified fatty acids have been removed, to produce a detoxified lipooligosaccharide (dLOS), or from which lipid A has been removed, to produce a detoxified oligosaccharide (OS), which is linked to an immunogenic carrier. The vaccine is useful for preventing otitis media and respiratory infections caused by M. catarrhalis in mammals, including humans.
Claims12
An immunogenic composition comprising a lipooligosaccharide (LOS) isolated from Moraxella catarrhalis and detoxified by treating to remove esterified fatty acids to produce detoxified LOS (dLOS) and an immunogenic carrier covalently linked thereto.
Dependencies are inferred from the claim text.